Blog

Blog

Drug Target Encyclopedia Series (40) —CD80

Linkedin

Release Time：

2026-06-23 10:29

 

  

CD80, also known as B7-1, is a member of the B7 family and an important immune co-stimulatory molecule involved in T-cell activation, antigen presentation, and immune response regulation. As a cell-surface ligand interacting with CD28, CTLA-4, and PD-L1, CD80 plays a dual role in balancing immune activation and immune suppression.

CD80 is highly relevant in cancer immunotherapy, autoimmune disease research, transplant immunology, and inflammatory disease studies. Its central position in the immune checkpoint and co-stimulatory signaling network makes it an attractive target for next-generation immunomodulatory drug development.

🧬CD80 is highly relevant in:

• Cancer immunotherapy

• Autoimmune disease research

• Transplant rejection research

• Inflammatory disease studies

• Antigen-presenting cell biology

• Immune checkpoint drug discovery

🎯 Targeting CD80 in drug development:

  • Fusion proteins – Modulate CD80/CD86-mediated signaling and regulate T-cell activation through checkpoint or co-stimulatory pathways.
  • Bispecific or engineered immune modulators – Explore CD80-related mechanisms to enhance anti-tumor immunity or reshape immune responses.
  • Monoclonal antibodies – Investigate CD80 as a surface immune target for blocking, activating, or immune-regulatory strategies.
  • Combination immunotherapy – Evaluate CD80-related approaches with checkpoint inhibitors, cytokine therapies, cancer vaccines, or cell therapy platforms.
  • Autoimmune disease strategies – Target CD80-mediated co-stimulation to suppress pathological immune activation and restore immune balance.

💥 Challenges include:

  1. Complex dual role in immune activation and inhibition
  2. Potential systemic immune-related toxicity
  3. Context-dependent signaling through CD28, CTLA-4, and PD-L1
  4. Difficulty separating anti-tumor immunity from autoimmunity risk
  5. Biomarker selection for patient stratification
  6. Optimizing therapeutic format, dosing, and combination strategy

 

🔬 CD80 is gaining increasing attention as a key immune-regulatory target at the intersection of co-stimulation and checkpoint biology. As engineered fusion proteins, antibodies, and next-generation immunotherapies continue to evolve, CD80 may play an important role in expanding immune modulation strategies for oncology, autoimmune diseases, and transplant-related indications.

 

🔍 Is CD80 part of your immuno-oncology or immune modulation drug discovery pipeline?

 

Fill out the form below, or visit the link: to browse the complete list of available in-stock products.  

 

Prev

Drug Target Encyclopedia Series (41) —BAFF

Drug Target Encyclopedia Series (39) —CDH6

Next